Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ('Innate' or the 'Company') announced the voting results of its shareholders at the Annual General Meeting ('AGM'), which took place on May 28, 2021, in Marseille, France without the physical presence of its shareholders. All resolutions were voted on in accordance with the Executive Board's recommendations.
A total of 178 votes were cast out of a total of 31,717,812 shares giving right to 32,180,682 voting rights, representing a quorum of 40.141%.
During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. Pascale Boissel's mandate lasts until the AGM in 2022 and Novo Nordisk A/S, represented by Marcus Schindler, M.D., decided not to seek re-election due to Dr. Schindler's new role as Chief Scientific Officer of Novo Nordisk A/S. Novo Nordisk A/S remains a shareholder in the Company but no longer has a seat on its Supervisory Board.
'Novo Nordisk A/S has been a long-standing member of Innate's Supervisory Board, and we thank them for their valued contributions to the Company,' said Hervé Brailly, Ph.D., Chairman of the Supervisory Board. 'We wish Dr. Schindler much success in his new role and appreciate his support of Innate.'
The AGM recording, the resolutions, the results of the votes and other documents relating to the AGM are available in the Annual General Meeting 2021 section of the Company's website: https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting
The Company's 2020 20-F is available on the Investors section of the website.
Innate Pharma SA published this content on 28 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2021 20:06:03 UTC.